MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor

被引:92
|
作者
Liu, Lingxiang [1 ]
Shao, Xiaoyan [2 ]
Gao, Wen [1 ]
Zhang, Zhi [3 ]
Liu, Ping [1 ]
Wang, Rongsheng [1 ]
Huang, Puwen [1 ]
Yin, Yongmei [1 ]
Shu, Yongqian [1 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 1, Ctr Canc, Nanjing, Jiangsu, Peoples R China
[2] Nanjing Univ, Sch Med, Affiliated DrumTower Hosp, Dept Hematol, Nanjing, Jiangsu, Peoples R China
[3] Nanjing Med Univ, Canc Hosp, Dept Thorac Surg, Nanjing, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
epidermal growth factor receptor (EGFR); microRNA; miR-133b; non-small-cell lung cancer; targeted therapy; DIFFERENTIAL EXPRESSION; CLINICAL-RESPONSE; EGFR EXPRESSION; COPY NUMBER; IN-VITRO; GEFITINIB; MIR-133B; SURVIVAL; GENE; MUTATIONS;
D O I
10.1111/j.1742-4658.2012.08741.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Both the deregulation of microRNAs and epidermal growth factor receptor (EGFR) are emerging as important factors in non-small-cell lung cancer (NSCLC). Here, miR-133b was found to be associated with tumor stage, the extent of regional lymph node involvement, stage, visceral pleura or vessel invasion and EGFR mRNA expression in Chinese patients with NSCLC. Bioinformatic analysis and luciferase reporter assay revealed that miR-133b can interact specifically with the 3'-UTR of EGFR mRNA. Functionally, miR-133b transfection showed regulatory activity in translationally repressing EGFR mRNA. Moreover, miR-133b transfection may modulate apoptosis, invasion and sensitivity to EGFR-TKI through the EGFR signaling pathways, especially in EGFR-addicted NSCLC cells. Taken together, our findings show that miR-133b can inhibit cell growth of NSCLC through targeting EGFR and regulating its downstream signaling pathway. This finding has important implications for the development of targeted therapeutics for a number of EGFR-addicted cancers.
引用
收藏
页码:3800 / 3812
页数:13
相关论文
共 50 条
  • [41] Epidermal growth factor receptor mutations and their correlation with epidermal growth factor receptor-tyrosine kinase inhibitor therapy and association with the characteristics of patients with non-small-cell lung cancer: A meta-analysis
    Zhang, Xiao-Hang
    Li, Cheng
    Dai, Chen-Fei
    Zhou, Bao-Sen
    THORACIC CANCER, 2011, 2 (03) : 101 - 108
  • [42] Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer
    Selvaggi, G
    Novello, S
    Torri, V
    Leonardo, E
    De Giuli, P
    Borasio, P
    Mossetti, C
    Ardissone, F
    Lausi, P
    Scaghottil, GV
    ANNALS OF ONCOLOGY, 2004, 15 (01) : 28 - 32
  • [43] Clinical Significance of BIM Deletion Polymorphism in Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation
    Isobe, Kazutoshi
    Hata, Yoshinobu
    Tochigi, Naobumi
    Kaburaki, Kyohei
    Kobayashi, Hiroshi
    Makino, Takashi
    Otsuka, Hajime
    Sato, Fumitomo
    Ishida, Fumiaki
    Kikuchi, Naoshi
    Hirota, Nao
    Sato, Keita
    Sano, Go
    Sugino, Keishi
    Sakamoto, Susumu
    Takai, Yujiro
    Shibuya, Kazutoshi
    Iyoda, Akira
    Homma, Sakae
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : 483 - 487
  • [44] Adjuvant Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer
    Lourdes, Laura S.
    Jalal, Shadia I.
    Hanna, Nasser
    ONCOLOGIST, 2015, 20 (09) : 975 - 978
  • [45] Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer
    Van Der Steen, Nele
    Giovannetti, Elisa
    Carbone, Daniela
    Leonetti, Alessandro
    Rolfo, Christian D.
    Peters, Godefridus J.
    CANCER DRUG RESISTANCE, 2018, 1 (04) : 230 - 249
  • [46] Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer
    Chen, Yuh-Min
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2013, 76 (05) : 249 - 257
  • [47] Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer
    Walia, Meenu
    Singhal, Manish K.
    Kamle, Mangesh S.
    INDIAN JOURNAL OF CANCER, 2022, 59 : S80 - S89
  • [48] Targeting epidermal growth factor receptor in non-small cell lung cancer : current advances and perspectives
    Italiano, Antoine
    Besse, Benjamin
    Planchard, David
    Soria, Jean-Charles
    BULLETIN DU CANCER, 2007, 94 : F177 - F188
  • [49] Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer
    Pallis, A. G.
    Fennell, D. A.
    Szutowicz, E.
    Leighl, N. B.
    Greillier, L.
    Dziadziuszko, R.
    BRITISH JOURNAL OF CANCER, 2011, 105 (01) : 1 - 8
  • [50] Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations
    Wu, Jenn-Yu
    Yu, Chong-Jen
    Shih, Jin-Yuan
    CLINICAL LUNG CANCER, 2019, 20 (06) : E620 - E630